Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$408 Mln
Revenue (TTM)
$825 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
--
EV/EBITDA
-23.5
Div. Yield
0 %
Debt to Equity
0.6
Book Value
$3.9
EPS
$-3.9
Face value
--
Shares outstanding
93,508,165
CFO
$771.51 Mln
EBITDA
$845.76 Mln
Net Profit
$180.83 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
| -25.4 | -0.4 | -25.4 | -48.3 | -41.8 | -31.5 | -18.9 |
|
BSE Sensex*
| -13.7 | -10.1 | -14.2 | -3.8 | 7.4 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
| -55.1 | -28.2 | 31.9 | -47.4 | 39.6 | -27.4 | -6.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
4.6 | 407.7 | 824.5 | -365.9 | -46.6 | -68.5 | -- | 1.1 |
| 7.8 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.1 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.9 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.6 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 75.7 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.0 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 329.0 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 118.3 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,... a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Address: 322 North 2200 West, Salt Lake City, UT, United States, 84116 Read more
CEO, President & Director
Mr. Paul J. Diaz
CEO, President & Director
Mr. Paul J. Diaz J.D.
Headquarters
Salt Lake City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Myriad Genetics Inc (MYGN) is $4.59 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Myriad Genetics Inc (MYGN) has given a return of -41.76% in the last 3 years.
Since, TTM earnings of Myriad Genetics Inc (MYGN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.57
|
1.56
|
|
2024
|
-9.81
|
1.78
|
|
2023
|
-6.26
|
2.10
|
|
2023
|
-16.97
|
2.15
|
|
2022
|
-10.56
|
1.34
|
The 52-week high and low of Myriad Genetics Inc (MYGN) are Rs 8.97 and Rs 3.76 as of 02-Apr-2026.
Myriad Genetics Inc (MYGN) has a market capitalisation of $ 408 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Myriad Genetics Inc (MYGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.09
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.